SCHEMBL1131765

SCHEMBL1131765

CC1(C(=O)O)CCCNC1

nearest known ligand 0.48

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
FFAR3 O14843 1/20 0.48
HSD17B10 Q99714 1/20 0.31
SIGMAR1 Q99720 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20502872 1.00 FFAR3 (0.48) FFAR3HSD17B10SIGMAR1
SCHEMBL15415368 1.00 FFAR3 (0.48) FFAR3HSD17B10SIGMAR1
Hydrochloric Acid SCHEMBL6995127 0.98 FFAR3 (0.46) FFAR3HSD17B10SIGMAR1
Hydrochloric Acid SCHEMBL31412240 0.98 FFAR3 (0.46) FFAR3HSD17B10SIGMAR1
Trifluoroacetic Acid SCHEMBL30849765 0.89 FFAR3 (0.39) FFAR3HSD17B10
SCHEMBL20293460 0.86
SCHEMBL20294369 0.86
SCHEMBL1462801 0.86
Hydrochloric Acid SCHEMBL1463754 0.84 FFAR3 (0.50) FFAR3
Hydrochloric Acid SCHEMBL22655436 0.84 FFAR3 (0.50) FFAR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114846013-B Novel aminoaryl derivatives useful as diacylglycerol acyltransferase 2 inhibitors and uses thereof 株式会社LG化学 2024-12-20 CN claimed
CN-109641873-B N- (pyridin-2-yl) pyridine-sulfonamide derivatives and their use for the treatment of disease 诺华股份有限公司 2022-03-18 CN claimed
EP-3504194-A1 N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE Novartis AG (CH) 2019-07-03 EP claimed
WO-2018042316-A1 N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE NOVARTIS AG (CH) 2018-03-08 WO claimed
EP-4596551-A1 COMPOUNDS WITH ANTI-KRAS MUTANT TUMOR ACTIVITY Trasveda Ltd. (KY) 2025-08-06 EP disclosed
EP-4551570-A1 NOVEL COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF Dong-A ST Co., Ltd. (KR) 2025-05-14 EP disclosed
WO-2025096855-A1 DEGRADERS AND USES THEREOF KUMQUAT BIOSCIENCES INC. (US) 2025-05-08 WO disclosed
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof DONG-A ST CO., LTD. (KR) 2025-03-04 US disclosed
CN-119403798-A Novel compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof 东亚ST 株式会社 2025-02-07 CN disclosed
CN-114846013-B Novel aminoaryl derivatives useful as diacylglycerol acyltransferase 2 inhibitors and uses thereof 株式会社LG化学 2024-12-20 CN disclosed
WO-2024067714-A1 COMPOUNDS WITH ANTI-KRAS MUTANT TUMOR ACTIVITY 泰励生物科技(上海)有限公司 2024-04-04 WO disclosed
CN-117800975-A Compounds with anti-KRAS mutant tumor activity 泰励生物科技(上海)有限公司 2024-04-02 CN disclosed
US-20030114496-A1 Novel cyclohexyl sulphones MERCK SHARP & DOHME (UK) LIMITED (GB) 2003-06-19 US disclosed
WO-2003018543-A1 NOVEL CYCLOHEXYL SULPHONES MERCK SHARP & DOHME LIMITED (GB) 2003-03-06 WO disclosed
WO-2002081435-A1 SULPHONES WHICH MODULATE THE ACTION OF GAMMA SECRETASE MERCK SHARP & DOHME LIMITED (GB) 2002-10-17 WO disclosed
US-6458830-B1 THE COMPOUNDS ARE OF PARTICULAR USE IN THE TREATMENT OR PREVENTION OF DEPRESSION, ANXIETY, PAIN, INFLAMMATION, MIGRAINE, EMESIS AND POSTHERPETIC NEURALGIA. MERCK SHARP & DOHME LTD. 2002-10-01 US disclosed
EP-1165540-A1 TETRAHYDROPYRAN DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS MERCK SHARP & DOHME LTD. (GB) 2002-01-02 EP disclosed
WO-2000056727-A1 TETRAHYDROPYRAN DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS MERCK SHARP & DOHME LIMITED (GB) 2000-09-28 WO disclosed
EP-0874809-A1 CARBAMOYLOXY DERIVATIVES OF MUTILINE AND THEIR USE AS ANTIBACTERIALS SMITHKLINE BEECHAM PLC (GB) 1998-11-04 EP disclosed
WO-1997025309-A1 CARBAMOYLOXY DERIVATIVES OF MUTILINE AND THEIR USE AS ANTIBACTERIALS SMITHKLINE BEECHAM PLC (GB) 1997-07-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof EIF2AK4, GCN1, GCGR FFAR3 3473/4885HSD17B10 289/4885SIGMAR1 3330/4885
US-20030114496-A1 Novel cyclohexyl sulphones BACE1, APP, PSEN1 FFAR3 4227/4885HSD17B10 487/4885SIGMAR1 2872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.